Deal-hungry Lilly strikes up to $2.9B immuno play for Merida

With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune diseases.